Ursula Hirschkorn (European Pharmaceutical Review)
NewsBiopharmaceutical PAT market forecast to reach $4.32bn
Growing demand for real-time process monitoring and more consistent biopharmaceutical manufacturing is expected to drive investment in process analytical technology.
NewsTerahertz spectroscopy and machine learning accelerate API analysis
A new analytical approach combining terahertz spectroscopy with machine learning could support faster, non-destructive monitoring of active pharmaceutical ingredient content.
NewsFDA warning letters highlight contamination control and facility maintenance failures
Findings from sterile drug manufacturing sites emphasise the agency’s expectation for companies to provide tangible evidence showing reduced quality and microbial risk and maintenance of control.
NewsBiologics growth expected to reshape pharmaceutical packaging demand
Evolving regulatory requirements and ensuring product sterility and stability are driving demand for packaging innovation, particularly for biologic medicines, research suggests.
NewsShionogi ranks second in 2026 Antimicrobial Resistance Benchmark report
Company’s efforts towards wastewater API controls and environmental risk management linked to AMR recognised by Access to Medicine Foundation’s Antimicrobial Resistance Benchmark 2026.
NewsStudy explores nanoparticle approach to pharmaceutical wastewater pollution
Marine bacteria and cerium oxide nanoparticles could reduce pharmaceutical contaminants and toxicity in wastewater, report shows.
ArticleBig potential for small molecule drugs in cancer treatment
With recent recommendation of Takeda’s fruquintinib by the European Medicines Agency (EMA), EPR spoke to Dr Sebastian Stintzing, Professor of Medicine, Head of the Department of Hematology, Oncology, and Tumor Immunology (CCM) of The Charité University Hospital in Berlin and investigator on the FRESCO-2 trial, to find out more about ...